Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET
|
Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
November 16, 2021 07:00 ET
|
Imara, Inc.
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
November 09, 2021 07:00 ET
|
Imara, Inc.
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline...
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
November 08, 2021 07:00 ET
|
Imara, Inc.
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
November 04, 2021 16:01 ET
|
Imara, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 04, 2021 09:17 ET
|
Imara, Inc.
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
Imara to Participate in Upcoming Investor Conferences
September 15, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at Upcoming Investor Conferences
September 03, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 06, 2021 07:00 ET
|
Imara, Inc.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 05, 2021 07:15 ET
|
Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...